0

Celgene Announces Positive Phase 2 Data In Patients With Crohn’s Disease

Today Celgene (NASDAQ:CELG) announced positive phase 2 results for their Crohn’s Disease study. This data was presented at the Digestive Disease Week — DDW — in Washington D.C. This trial was run as a double-blind placebo controlled trial in which… Continue Reading

0

Shares of Newlink Genetics Tumble 26% After Announcing Trial Continuation Of Pancreatic Cancer Study

Shares of Newlink Genetics (NASDAQ:NLNK) are down 26% after an interim look revealed that the study should continue as planned. At first this may sound really bullish, but on the other hand Wall Street was looking for an early stop… Continue Reading

0

Merrimack Continues To Make Progress With Pancreatic Cancer Drug

(BiotechPickList) – Today Merrimack Pharmaceuticals (NASDAQ:MACK) announced that it has initiated a phase 2 trial in patients with metastatic pancreatic cancer. These patients are being directly targeted as an IGF-1 biomarker population. This means that these patients have high levels of… Continue Reading

0

Can-Fite Biopharma Reports Positive Phase 2/3 Results In Patients with Psoriasis

On April 27,  2015 Can-Fite Biopharma (NASDAQ:CANF) reported positive results in a phase 2/3 trial in patients with moderate-severe psoriasis. As soon as the news was announced shares of Can-Fite surged high ending the day up 51.62%. The new data… Continue Reading

0

Alnylam Reports Positive Phase 2 Results In Patisiran Study

Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) are up roughly 2% after the company reported positive results in their phase 2 open label extension study –OLE — of Patisiran. This phase 2 trial is treating patients with a disease known as TTR-Amyloidosis,… Continue Reading

0

FDA Approves Amgen’s Corlanor Drug For Heart Failure

Amgen (NASDAQ:AMGN) closed the trading day at $165.47, up 1.78% as the company announced today that the FDA had approved a heart-failure drug known as Corlanor — ivabradine. The drug Corlanor is an all oral type drug that is intended… Continue Reading

0

Regulus And AstraZeneca To Advance Big Potential NASH Drug

Shares of Regulus Therapeutics (NASDAQ:RGLS) surged about 8% in after hours trade today after the company reported that Astrazeneca (NYSE:AZN) wants to advance RG-125 — also known as AZD4076 — for the ability to treat patients with NASH who additionally… Continue Reading

0

Intrexon Partners with Merck Serono on CAR-T Development Deal

Shares of Intrexon Corp (NYSE:XON) soared as much as 8% yesterday after the company had announced that it had formed a collaboration deal with Merck Serono – a German biotechnology company with no relationship to Merck (NYSE:MRK). Intrexon had partnered… Continue Reading

0

RXi Pharmaceuticals Provides Positive Update On Phase 2a Trials And Collaborations

On March 23, 2015 RXi Pharmaceuticals (NASDAQ:RXII) first announced preliminary findings from its phase 2a keloid trial study known as RXI-109-1401. This trial is evaluating  the ability to reduce patients’ recurrence of keloids following keloidectomy. This phase 2a trial is ongoing… Continue Reading

0

Esperion Therapeutics Announces Positive Phase 2b Results In Patients with Hypercholesterolemia

Shares of Esperion Therapeutics (ESPR) are up about 22% after the company reported positive phase 2b results in Hypercholesterolemia. Esperion is using its own drug ECT-1002 which is given to patients in conjunction with these patients taking current Statin therapy.… Continue Reading